PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Würfel, M.* ; Blüher, M. ; Stumvoll, M.* ; Ebert, T.* ; Kovacs, P.* ; Tönjes, A.* ; Breitfeld, J.*

Adipokines as clinically relevant therapeutic targets in obesity.

Biomedicines 11:26 (2023)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Adipokines provide an outstanding role in the comprehensive etiology of obesity and may link adipose tissue dysfunction to further metabolic and cardiovascular complications. Although several adipokines have been identified in terms of their physiological roles, many regulatory circuits remain unclear and translation from experimental studies to clinical applications has yet to occur. Nevertheless, due to their complex metabolic properties, adipokines offer immense potential for their use both as obesity-associated biomarkers and as relevant treatment strategies for overweight, obesity and metabolic comorbidities. To provide an overview of the current clinical use of adipokines, this review summarizes clinical studies investigating the potential of various adipokines with respect to diagnostic and therapeutic treatment strategies for obesity and linked metabolic disorders. Furthermore, an overview of adipokines, for which a potential for clinical use has been demonstrated in experimental studies to date, will be presented. In particular, promising data revealed that fibroblast growth factor (FGF)-19, FGF-21 and leptin offer great potential for future clinical application in the treatment of obesity and related comorbidities. Based on data from animal studies or other clinical applications in addition to obesity, adipokines including adiponectin, vaspin, resistin, chemerin, visfatin, bone morphogenetic protein 7 (BMP-7) and tumor necrosis factor alpha (TNF-α) provide potential for human clinical application.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
4.700
0.000
4
3
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter Adipokines ; Biomarker ; Obesity ; Therapeutic Strategy; Tumor-necrosis-factor; Reduces Food-intake; Congenital Leptin Deficiency; Bone Morphogenetic Protein-7; Adipose-tissue Expression; Insulin-resistance; Metabolic Syndrome; Factor-alpha; Body-weight; Circulating Fgf21
Sprache englisch
Veröffentlichungsjahr 2023
HGF-Berichtsjahr 2023
ISSN (print) / ISBN 2227-9059
e-ISSN 2227-9059
Zeitschrift Biomedicines
Quellenangaben Band: 11, Heft: 5, Seiten: , Artikelnummer: 26 Supplement: ,
Verlag MDPI
Verlagsort Basel, Switzerland
Begutachtungsstatus Peer reviewed
Institut(e) Helmholtz Institute for Metabolism, Obesity and Vascular Research (HI-MAG)
POF Topic(s) 30201 - Metabolic Health
Forschungsfeld(er) Helmholtz Diabetes Center
PSP-Element(e) G-506501-001
Förderungen Deutsche Forschungsgemeinschaft (DFG, German Research foundation)
DOI 10.3390/biomedicines11051427
WOS ID 001011345200001
Scopus ID 85160796410
PubMed ID 37239098
Erfassungsdatum 2023-10-06
[➜Korrektur melden]